{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:26:12Z","timestamp":1787635572523,"version":"build-2736575974"},"reference-count":142,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Disease-a-Month"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.disamonth.2018.06.001","type":"journal-article","created":{"date-parts":[[2018,7,21]],"date-time":"2018-07-21T03:02:52Z","timestamp":1532142172000},"page":"51-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"title":["Biologics for the primary care physician: Review and treatment of psoriasis"],"prefix":"10.1016","volume":"65","author":[{"given":"Eric D.","family":"Schadler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Ortel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie L.","family":"Mehlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.disamonth.2018.06.001_bib0001","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1038\/jid.2015.296","article-title":"Psoriasis in the U.S. Medicare population: prevalence, treatment, and factors associated with biologic use","volume":"135","author":"Takeshita","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.disamonth.2018.06.001_bib0002","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s13671-013-0066-6","article-title":"Genetic Epidemiology of psoriasis","volume":"3","author":"Gupta","year":"2014","journal-title":"Curr Dermatol Rep"},{"issue":"6","key":"10.1016\/j.disamonth.2018.06.001_bib0003","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.clindermatol.2007.08.007","article-title":"Psoriasis: epidemiology","volume":"25","author":"Gudjonsson","year":"2007","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.disamonth.2018.06.001_bib0004","series-title":"Dermatology","author":"Bolognia","year":"2012"},{"issue":"7","key":"10.1016\/j.disamonth.2018.06.001_bib0005","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1093\/rheumatology\/ket363","article-title":"Age at disease onset: a key factor for understanding psoriatic disease","volume":"53","author":"Queiro","year":"2014","journal-title":"Rheumatol (Oxf)"},{"issue":"3","key":"10.1016\/j.disamonth.2018.06.001_bib0006","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jaad.2008.10.062","article-title":"Trends in incidence of adult-onset psoriasis over three decades: a population-based study","volume":"60","author":"Icen","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.disamonth.2018.06.001_bib0007","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1086\/503821","article-title":"Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene","volume":"78","author":"Nair","year":"2006","journal-title":"Am J Hum Genet"},{"issue":"4","key":"10.1016\/j.disamonth.2018.06.001_bib0008","first-page":"214","article-title":"Inheritance of psoriasis. Analysis of 2035 family histories","volume":"33","author":"Andressen","year":"1982","journal-title":"Hautarzt"},{"issue":"2","key":"10.1016\/j.disamonth.2018.06.001_bib0009","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bjd.12375","article-title":"Heritability of psoriasis in a large twin sample","volume":"169","author":"L\u00f8nnberg","year":"2013","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.disamonth.2018.06.001_bib0010","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0738-081X(97)00024-2","article-title":"Triggering factors","volume":"15","author":"Tagami","year":"1997","journal-title":"Clin Dermatol"},{"issue":"10","key":"10.1016\/j.disamonth.2018.06.001_bib0011","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/jdv.12001","article-title":"Obesity, waist circumference, weight change, and the risk of psoriasis in US women","volume":"27","author":"Kumar","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"15","key":"10.1016\/j.disamonth.2018.06.001_bib0012","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1001\/archinte.167.15.1670","article-title":"Obesity, waist circumference, weight change, and the risk of psoriasis in women: nurses\u2019 health study II","volume":"167","author":"Setty","year":"2007","journal-title":"Arch Intern Med"},{"issue":"1\u20134","key":"10.1016\/j.disamonth.2018.06.001_bib0013","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3109\/rhe1.1955.1.issue-1-4.15","article-title":"The Significance of Infections in the Origination of Psoriasis","volume":"1","author":"Norrlind","year":"1955","journal-title":"Acta Rheumatol Scand"},{"issue":"2","key":"10.1016\/j.disamonth.2018.06.001_bib0014","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1084\/jem.181.2.747","article-title":"Bacterial superantigens induce T cell expression of the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen, via stimulation of interleukin 12 production","volume":"181","author":"Leung","year":"1995","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.disamonth.2018.06.001_bib0015","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.clindermatol.2007.08.015","article-title":"Triggering psoriasis: the role of infections and medications","volume":"25","author":"Fry","year":"2007","journal-title":"Clin Dermatol"},{"issue":"6","key":"10.1016\/j.disamonth.2018.06.001_bib0016","first-page":"317","article-title":"Photosensitive psoriasis\u2013clinical findings and phototest results","volume":"3","author":"Ros","year":"1986","journal-title":"Photodermatol"},{"issue":"2","key":"10.1016\/j.disamonth.2018.06.001_bib0017","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2133.2009.09194.x","article-title":"Individual differences in the effect of daily stressors on psoriasis: a prospective study","volume":"161","author":"Verhoeven","year":"2009","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.disamonth.2018.06.001_bib0018","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.mehy.2009.02.051","article-title":"Role of corticotropin-releasing hormone and receptor in the pathogenesis of psoriasis","volume":"73","author":"Zhou","year":"2009","journal-title":"Med Hypotheses"},{"issue":"5","key":"10.1016\/j.disamonth.2018.06.001_bib0019","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/j.1365-2133.2010.09984.x","article-title":"How stress gets under the skin: cortisol and stress reactivity in psoriasis","volume":"163","author":"Evers","year":"2010","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.disamonth.2018.06.001_bib0020","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1365-2133.1977.tb15186.x","article-title":"Psoriasis and stress","volume":"97","author":"Seville","year":"1977","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.disamonth.2018.06.001_bib0021","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1001\/archderm.135.12.1479","article-title":"Association of early-stage psoriasis with smoking and male alcohol consumption: evidence from an Italian case-control study","volume":"135","author":"Naldi","year":"1999","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.disamonth.2018.06.001_bib0022","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1046\/j.1365-2230.2000.00588.x","article-title":"Alcohol, smoking and psoriasis","volume":"25","author":"null","year":"2001","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"10.1016\/j.disamonth.2018.06.001_bib0023","first-page":"11","article-title":"The role of hormones in the pathogenesis of psoriasis vulgaris","volume":"89","author":"Roman","year":"2016","journal-title":"Clujul Med"},{"issue":"2","key":"10.1016\/j.disamonth.2018.06.001_bib0024","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1067\/mjd.2000.106374","article-title":"Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?","volume":"43","author":"Krueger","year":"2000","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.disamonth.2018.06.001_bib0025","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/archderm.141.1.82","article-title":"Definitions of measures of effect duration for psoriasis treatments","volume":"141","author":"Gordon","year":"2005","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.disamonth.2018.06.001_bib0026","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.autrev.2014.01.008","article-title":"Diagnosis and classification of psoriasis","volume":"13","author":"Raychaudhuri","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"10","key":"10.1016\/j.disamonth.2018.06.001_bib0027","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/j.1346-8138.2010.00871.x","article-title":"Clinical course of guttate psoriasis: long-term follow-up study","volume":"37","author":"Ko","year":"2010","journal-title":"J Dermatol"},{"key":"10.1016\/j.disamonth.2018.06.001_bib0028","first-page":"131","article-title":"Pustular psoriasis: pathophysiology and current treatment perspectives","volume":"6","author":"Benjegerdes","year":"2016","journal-title":"Psoriasis (Auckl)"},{"issue":"1","key":"10.1016\/j.disamonth.2018.06.001_bib0029","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1684\/ejd.2015.2698","article-title":"Enhancement of mRNA expression of survivin and human beta-defensin-3 in lesions of psoriasis vulgaris","volume":"26","author":"Wang","year":"2016","journal-title":"Eur J Dermatol"},{"issue":"2","key":"10.1016\/j.disamonth.2018.06.001_bib0030","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1590\/abd1806-4841.20142633","article-title":"Nail psoriasis: a review of the literature","volume":"89","author":"Schons","year":"2014","journal-title":"An Bras Dermatol"},{"issue":"2","key":"10.1016\/j.disamonth.2018.06.001_bib0031","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/art.24172","article-title":"Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study","volume":"61","author":"Wilson","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.disamonth.2018.06.001_bib0032","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/rheumatology\/keh198","article-title":"Extended report: nail disease in psoriatic arthritis\u2013clinically important, potentially treatable and often overlooked","volume":"43","author":"Williamson","year":"2004","journal-title":"Rheumatol (Oxf)"},{"issue":"5","key":"10.1016\/j.disamonth.2018.06.001_bib0033","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.disamonth.2018.06.001_bib0034","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1172\/JCI117308","article-title":"Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines","volume":"94","author":"Nestle","year":"1994","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.disamonth.2018.06.001_bib0035","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1084\/jem.20090480","article-title":"Self-RNA\u2013antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8","volume":"206","author":"Ganguly","year":"2009","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.disamonth.2018.06.001_bib0036","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.coi.2008.06.008","article-title":"Antimicrobial peptides and self-DNA in autoimmune skin inflammation","volume":"20","author":"Gilliet","year":"2008","journal-title":"Curr Opin Immunol"},{"issue":"6","key":"10.1016\/j.disamonth.2018.06.001_bib0037","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/jid.2009.59","article-title":"The IL-23\/Th17 axis in the immunopathogenesis of psoriasis","volume":"129","author":"Di Cesare","year":"2009","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.disamonth.2018.06.001_bib0038","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.det.2014.09.002","article-title":"The Immunopathogenesis of Psoriasis","volume":"33","author":"Kim","year":"2015","journal-title":"Dermatol Clin"},{"issue":"3","key":"10.1016\/j.disamonth.2018.06.001_bib0039","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/cmi.2010.21","article-title":"Interleukin-17 and its expanding biological functions","volume":"7","author":"Xu","year":"2010","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"10.1016\/j.disamonth.2018.06.001_bib0040","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1146\/annurev.immunol.25.022106.141557","article-title":"IL-17 family cytokines and the expanding diversity of effector T cell lineages","volume":"25","author":"Weaver","year":"2007","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"10.1016\/j.disamonth.2018.06.001_bib0041","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.immuni.2006.01.001","article-title":"TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells","volume":"24","author":"Veldhoen","year":"2006","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.disamonth.2018.06.001_bib0042","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.cyto.2007.11.013","article-title":"Structure\u2013function relationships in the IL-17 receptor: Implications for signal transduction and therapy","volume":"41","author":"Shen","year":"2008","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.disamonth.2018.06.001_bib0043","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.cyto.2015.01.030","article-title":"Interleukin 12 (IL-12) family cytokines: role in immune pathogenesis and treatment of CNS autoimmune disease","volume":"75","author":"Sun","year":"2015","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.disamonth.2018.06.001_bib0044","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1081-1206(10)62426-X","article-title":"T-cell subsets (Th1 versus Th2)","volume":"85","author":"Romagnani","year":"2000","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.disamonth.2018.06.001_bib0045","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.disamonth.2018.06.001_bib0046","doi-asserted-by":"crossref","DOI":"10.3410\/B2-40","article-title":"The role of IL-23 in the immunopathogenesis of psoriasis","volume":"2","author":"Meglio","year":"2010","journal-title":"F1000 Biol Rep"},{"issue":"12","key":"10.1016\/j.disamonth.2018.06.001_bib0047","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1084\/jem.20060244","article-title":"IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2\u2013dependent mechanisms with implications for psoriasis pathogenesis","volume":"203","author":"Chan","year":"2006","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.disamonth.2018.06.001_bib0048","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2133.1995.tb02696.x","article-title":"Keratins (K16 and K17) as markers of keratinocyte hyperproliferation in psoriasis in vivo and in vitro","volume":"133","author":"Leigh","year":"1995","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.disamonth.2018.06.001_bib0049","doi-asserted-by":"crossref","DOI":"10.3410\/M1-30","article-title":"The role of TNF inhibitors in psoriasis therapy: new implications for associated comorbidities","volume":"1","author":"Yost","year":"2009","journal-title":"F1000 Med Rep"},{"issue":"2","key":"10.1016\/j.disamonth.2018.06.001_bib0050","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1615\/CritRevEukarGeneExpr.v20.i2.10","article-title":"Tumor necrosis factor-\u03b1 signaling in macrophages","volume":"20","author":"Parameswaran","year":"2010","journal-title":"Crit Rev Eukaryot Gene Expr"},{"issue":"13","key":"10.1016\/j.disamonth.2018.06.001_bib0051","doi-asserted-by":"crossref","first-page":"7767","DOI":"10.1074\/jbc.271.13.7767","article-title":"Inhibition of macrophage scavenger receptor activity by tumor necrosis factor- is transcriptionally and post-transcriptionally regulated","volume":"271","author":"Hsu","year":"1996","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/j.disamonth.2018.06.001_bib0052","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.1074\/jbc.275.7.4858","article-title":"Tumor necrosis factor-\u03b1 induces differentiation of and bone resorption by osteoclasts","volume":"275","author":"Azuma","year":"2000","journal-title":"J Biol Chem"},{"issue":"17","key":"10.1016\/j.disamonth.2018.06.001_bib0053","doi-asserted-by":"crossref","first-page":"11846","DOI":"10.1074\/jbc.M512624200","article-title":"Tumor necrosis factor-\u03b1 increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c-Fms expression","volume":"281","author":"Yao","year":"2006","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.disamonth.2018.06.001_bib0054","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jaad.2008.01.006","article-title":"National psoriasis foundation clinical consensus on psoriasis co-morbidities and recommendations for screening","volume":"58","author":"Kimball","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.disamonth.2018.06.001_bib0056","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jaad.2005.03.046","article-title":"Epidemiology of psoriatic arthritis in the population of the United States","volume":"53","author":"Gelfand","year":"2005","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.disamonth.2018.06.001_bib0057","doi-asserted-by":"crossref","first-page":"537","DOI":"10.5312\/wjo.v5.i4.537","article-title":"Psoriatic arthritis: epidemiology, diagnosis, and treatment","volume":"5","author":"Liu","year":"2014","journal-title":"World J Orthop"},{"issue":"5","key":"10.1016\/j.disamonth.2018.06.001_bib0058","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/j.1365-2133.2008.09023.x","article-title":"Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque\u2010type psoriasis","volume":"160","author":"Reich","year":"2009","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.disamonth.2018.06.001_bib0059","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/ar2580","article-title":"Psoriatic arthritis: from pathogenesis to therapy","volume":"11","author":"FitzGerald","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"10.1016\/j.disamonth.2018.06.001_bib0060","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: Development of new criteria from a large international study","volume":"54","author":"William","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.disamonth.2018.06.001_bib0061","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1136\/ard.2008.089441","article-title":"Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS)","volume":"68","author":"Gladman","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.disamonth.2018.06.001_bib0062","first-page":"2577","article-title":"Inflammatory joint manifestations are prevalent in psoriasis: prevalence study of joint and axial involvement in psoriatic patients, and evaluation of a psoriatic and arthritic questionnaire","volume":"29","author":"Alenius","year":"2002","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.disamonth.2018.06.001_bib0063","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jaad.2007.04.001","article-title":"The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool","volume":"57","author":"Husni","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"17","key":"10.1016\/j.disamonth.2018.06.001_bib0064","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American heart association\/national heart, lung, and blood institute scientific statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.disamonth.2018.06.001_bib0065","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1001\/jama.2015.4260","article-title":"Prevalence of the metabolic syndrome in the United States, 2003-2012","volume":"313","author":"Aguilar","year":"2015","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.disamonth.2018.06.001_bib0066","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181039","article-title":"An update on psoriasis and metabolic syndrome: a meta-analysis of observational studies","volume":"12","author":"Singh","year":"2017","journal-title":"PLOS ONE"},{"issue":"7","key":"10.1016\/j.disamonth.2018.06.001_bib0067","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/jid.2010.103","article-title":"Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions","volume":"130","author":"Davidovici","year":"2010","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.disamonth.2018.06.001_bib0068","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/BOR.0b013e3283031c99","article-title":"Psoriasis and metabolic disease: epidemiology and pathophysiology","volume":"20","author":"Azfar","year":"2008","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"10.1016\/j.disamonth.2018.06.001_bib0069","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.ijcard.2013.01.197","article-title":"Role of psoriasis as independent predictor of cardiovascular disease: a meta-regression analysis","volume":"168","author":"Gaeta","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.disamonth.2018.06.001_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2018.02.040","article-title":"Interleukin-17, inflammation, and cardiovascular risk in patients with psoriasis","author":"Lockshin","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.disamonth.2018.06.001_bib0071","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1365-2796.2011.02368.x","article-title":"Prognosis following first-time myocardial infarction in patients with psoriasis: a Danish nationwide cohort study","volume":"270","author":"Ahlehoff","year":"2011","journal-title":"J Intern Med"},{"issue":"7","key":"10.1016\/j.disamonth.2018.06.001_bib0072","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1600-0625.2011.01308.x","article-title":"A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis","volume":"20","author":"Armstrong","year":"2011","journal-title":"Exp Dermatol"},{"issue":"4","key":"10.1016\/j.disamonth.2018.06.001_bib0073","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2133.2007.08068.x","article-title":"Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review","volume":"157","author":"Sterry","year":"2007","journal-title":"Br. J. Dermatol"},{"issue":"3","key":"10.1016\/j.disamonth.2018.06.001_bib0074","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/bjd.12735","article-title":"Diet and physical exercise in psoriasis: a randomized controlled trial","volume":"170","author":"Naldi","year":"2014","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.disamonth.2018.06.001_bib0075","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/jamadermatol.2016.0670","article-title":"Psoriasis, diabetes, and obesity: weighing the evidence","volume":"152","author":"Gelfand","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.disamonth.2018.06.001_bib0076","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jpsychores.2017.01.007","article-title":"Toward a better understanding of social anxiety and depression in psoriasis patients: the role of determinants, mediators, and moderators","volume":"94","author":"\u0141akuta","year":"2017","journal-title":"J Psychosom Res"},{"issue":"4","key":"10.1016\/j.disamonth.2018.06.001_bib0077","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/jid.2014.530","article-title":"The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries","volume":"135","author":"Dalgard","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.disamonth.2018.06.001_bib0078","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1365-4362.1993.tb02790.x","article-title":"Suicidal ideation in psoriasis","volume":"32","author":"Gupta Madhulika","year":"2007","journal-title":"Int J Dermatol"},{"issue":"2","key":"10.1016\/j.disamonth.2018.06.001_bib0079","doi-asserted-by":"crossref","DOI":"10.2196\/resprot.8490","article-title":"Psychosocial distress of patients with psoriasis: protocol for an assessment of care needs and the development of a supportive intervention","volume":"7","author":"Zill","year":"2018","journal-title":"JMIR Res Protoc"},{"issue":"1","key":"10.1016\/j.disamonth.2018.06.001_bib0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1586\/1744666X.2016.1112739","article-title":"Interleukin 17-A inhibition in the treatment of psoriasis","volume":"12","author":"Yiu","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"10.1016\/j.disamonth.2018.06.001_bib0081","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jaad.2009.07.022","article-title":"The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: A randomized clinical trial","volume":"62","author":"Menter","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.disamonth.2018.06.001_bib0082","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaad.2009.09.014","article-title":"Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial","volume":"63","author":"Langley","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.disamonth.2018.06.001_bib0083","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjd.14528","article-title":"Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study","volume":"175","author":"Egeberg","year":"2016","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.disamonth.2018.06.001_bib0084","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ajhg.2012.02.020","article-title":"Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci","volume":"90","author":"Ellinghaus","year":"2012","journal-title":"Am J Hum Genet"},{"issue":"6","key":"10.1016\/j.disamonth.2018.06.001_bib0085","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000249365","article-title":"Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes","volume":"172","author":"Lindeg\u00e5rd","year":"1986","journal-title":"Dermatologica"},{"key":"10.1016\/j.disamonth.2018.06.001_bib0086","first-page":"9","article-title":"Psoriatics in Norway. A questionnaire study on health status, contact with paramedical professions, and alcohol and tobacco consumption","volume":"142","author":"Braathen","year":"1989","journal-title":"Acta Derm Venereol Suppl (Stockh)"},{"issue":"10","key":"10.1016\/j.disamonth.2018.06.001_bib0087","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1038\/sj.jid.5700410","article-title":"The risk of lymphoma in patients with psoriasis","volume":"126","author":"Gelfand","year":"2006","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.disamonth.2018.06.001_bib0088","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1046\/j.1365-2133.1999.02655.x","article-title":"Malignant tumours and psoriasis: a follow-up study","volume":"140","author":"Frentz","year":"1999","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.disamonth.2018.06.001_bib0089","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1590\/S0365-05962012000600009","article-title":"Psoriasis and uveitis: a literature review","volume":"87","author":"Fraga","year":"2012","journal-title":"An Bras Dermatol"},{"issue":"2","key":"10.1016\/j.disamonth.2018.06.001_bib0090","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S0021-5155(00)00359-2","article-title":"Factors associated with increased aqueous flare in psoriasis","volume":"45","author":"Okamoto","year":"2001","journal-title":"Jpn J Ophthalmol"},{"issue":"6","key":"10.1016\/j.disamonth.2018.06.001_bib0091","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.jaad.2010.10.032","article-title":"Ocular psoriasis","volume":"65","author":"Rehal","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.disamonth.2018.06.001_bib0092","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1365-2133.2004.06093.x","article-title":"Prevalence of symptoms experienced by patients with different clinical types of psoriasis","volume":"151","author":"Sampogna","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.disamonth.2018.06.001_bib0093","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1468-3083.2012.04525.x","article-title":"Adherence to topical treatment in psoriasis: a systematic literature review","volume":"26","author":"Devaux","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.disamonth.2018.06.001_bib0094","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaad.2005.12.021","article-title":"Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis","volume":"55","author":"Brown","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.disamonth.2018.06.001_bib0095","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.clindermatol.2007.08.005","article-title":"The histopathologic spectrum of psoriasis","volume":"25","author":"Murphy","year":"2007","journal-title":"Clin Dermatol"},{"issue":"1","key":"10.1016\/j.disamonth.2018.06.001_bib0096","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0190-9622(03)02801-9","volume":"50","author":"Parakeratosis","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.disamonth.2018.06.001_bib0097","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/1523-1747.ep12283594","article-title":"Cell kinetic basis for pathophysiology of psoriasis","volume":"85","author":"Weinstein","year":"1985","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.disamonth.2018.06.001_bib0098","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s13555-017-0205-2","article-title":"Dermatologist and patient preferences in choosing treatments for moderate to severe psoriasis","volume":"7","author":"Alcusky","year":"2017","journal-title":"Dermatol Ther"},{"issue":"4","key":"10.1016\/j.disamonth.2018.06.001_bib0099","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3109\/09546634.2015.1054782","article-title":"Biologics and biosimilars","volume":"26","author":"Patel","year":"2015","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.disamonth.2018.06.001_bib0100","series-title":"Biologic Therapies of Immunologic Diseases, An Issue of Immunology and Allergy Clinics of North America, E-Book","author":"Chipps","year":"2017"},{"issue":"10","key":"10.1016\/j.disamonth.2018.06.001_bib0101","doi-asserted-by":"crossref","first-page":"807","DOI":"10.7326\/0003-4819-138-10-200305200-00008","article-title":"Case reports of heart failure after therapy with a tumor necrosis factor antagonist","volume":"138","author":"Kwon","year":"2003","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.disamonth.2018.06.001_bib0102","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"9494","key":"10.1016\/j.disamonth.2018.06.001_bib0103","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/j.disamonth.2018.06.001_bib0104","doi-asserted-by":"crossref","first-page":"31.e1","DOI":"10.1016\/j.jaad.2006.07.017","article-title":"A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis","volume":"56","author":"Menter","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.disamonth.2018.06.001_bib0105","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1136\/annrheumdis-2017-211384","article-title":"Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study","volume":"76","author":"Clowse","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.disamonth.2018.06.001_bib0106","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/annrheumdis-2017-212196","article-title":"Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study","volume":"77","author":"Mariette","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"9894","key":"10.1016\/j.disamonth.2018.06.001_bib0107","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.disamonth.2018.06.001_bib0108","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.disamonth.2018.06.001_bib0109","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaad.2015.07.002","article-title":"Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study","volume":"73","author":"Landells","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.disamonth.2018.06.001_bib0110","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N Engl J Med"},{"issue":"9625","key":"10.1016\/j.disamonth.2018.06.001_bib0111","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"issue":"9625","key":"10.1016\/j.disamonth.2018.06.001_bib0112","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.disamonth.2018.06.001_bib0113","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1136\/annrheumdis-2015-209055","article-title":"Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1)","volume":"76","author":"Strand","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.disamonth.2018.06.001_bib0114","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/rheumatology\/kex301","article-title":"Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study","volume":"56","author":"McInnes","year":"2017","journal-title":"Rheumatol (Oxf)"},{"issue":"4","key":"10.1016\/j.disamonth.2018.06.001_bib0115","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jaad.2017.05.033","article-title":"The effect of secukinumab on moderate-to-severe scalp psoriasis: results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study","volume":"77","author":"Bagel","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"9993","key":"10.1016\/j.disamonth.2018.06.001_bib0116","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.disamonth.2018.06.001_bib0117","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of lxekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.disamonth.2018.06.001_bib0118","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3899\/jrheum.170429","article-title":"Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase III study (SPIRIT-P1)","volume":"45","author":"van der Heijde","year":"2018","journal-title":"J Rheumatol"},{"issue":"10086","key":"10.1016\/j.disamonth.2018.06.001_bib0119","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.disamonth.2018.06.001_bib0120","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjd.14493","article-title":"A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis","volume":"175","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"issue":"14","key":"10.1016\/j.disamonth.2018.06.001_bib0121","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N Engl J Med"},{"issue":"10091","key":"10.1016\/j.disamonth.2018.06.001_bib0122","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.disamonth.2018.06.001_bib0123","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2018.03.037","article-title":"Dual neutralization of both IL-17A and IL-17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded placebo-controlled phase 2b trial","author":"Papp","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"16","key":"10.1016\/j.disamonth.2018.06.001_bib0124","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.disamonth.2018.06.001_bib0125","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2133.2004.06174.x","article-title":"Better medication adherence results in greater improvement in severity of psoriasis","volume":"151","author":"Carroll","year":"2004","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.disamonth.2018.06.001_bib0126","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/phpp.12088","article-title":"Phototherapy, psoriasis, and the age of biologics","volume":"30","author":"Richard Elisabeth","year":"2013","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"1","key":"10.1016\/j.disamonth.2018.06.001_bib0127","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2310\/7750.2012.11124","article-title":"Phototherapy in psoriasis: a review of mechanisms of action","volume":"17","author":"Wong","year":"2013","journal-title":"J Cutan Med Surg"},{"issue":"4","key":"10.1016\/j.disamonth.2018.06.001_bib0128","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s40265-017-0709-1","article-title":"Apremilast: a review in psoriasis and psoriatic arthritis","volume":"77","author":"Keating","year":"2017","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.disamonth.2018.06.001_bib0129","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.disamonth.2018.06.001_bib0130","doi-asserted-by":"crossref","first-page":"392","DOI":"10.5114\/pdia.2014.47121","article-title":"The possibilities and principles of methotrexate treatment of psoriasis \u2013 the updated knowledge","volume":"31","author":"Czarnecka-Operacz","year":"2014","journal-title":"Postepy Dermatol Alergol"},{"issue":"4","key":"10.1016\/j.disamonth.2018.06.001_bib0131","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10238-013-0252-7","article-title":"Impact of methotrexate on oxidative stress and apoptosis markers in psoriatic patients","volume":"14","author":"Elango","year":"2014","journal-title":"Clin Exp Med"},{"issue":"5","key":"10.1016\/j.disamonth.2018.06.001_bib0132","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/j.1365-2133.2011.10615.x","article-title":"Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)","volume":"165","author":"Barker","year":"2011","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.disamonth.2018.06.001_bib0133","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2165\/00003495-199243040-00010","article-title":"Acitretin: a review of its pharmacology and therapeutic use","volume":"43","author":"Pilkington","year":"1992","journal-title":"Drugs"},{"issue":"21","key":"10.1016\/j.disamonth.2018.06.001_bib0134","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept as monotherapy in patients with psoriasis","volume":"349","author":"Leonardi","year":"2003","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.disamonth.2018.06.001_bib0135","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","article-title":"A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction","volume":"152","author":"Papp","year":"2005","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.disamonth.2018.06.001_bib0136","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/pds.2046","article-title":"Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data","volume":"20","author":"Askling","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"10.1016\/j.disamonth.2018.06.001_bib0137","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jaad.2010.12.005","article-title":"Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL","volume":"66","author":"Gordon","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.disamonth.2018.06.001_bib0138","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2018.04.012","article-title":"Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from two phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)","author":"Gottlieb","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"0","key":"10.1016\/j.disamonth.2018.06.001_bib0139","article-title":"Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks of a phase 3, multicenter, randomized, double-blinded, etanercept- and placebo-controlled study (CIMPACT)","volume":"0","author":"Lebwohl","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.disamonth.2018.06.001_bib0140","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis \u2014 results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.disamonth.2018.06.001_bib0141","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/bjd.15706","article-title":"Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study","volume":"177","author":"Bissonnette","year":"2017","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.disamonth.2018.06.001_bib0142","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.disamonth.2018.06.001_bib0143","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"}],"container-title":["Disease-a-Month"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011502918300956?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011502918300956?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T00:52:21Z","timestamp":1661647941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011502918300956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":142,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0011502918300956"],"URL":"https:\/\/doi.org\/10.1016\/j.disamonth.2018.06.001","relation":{},"ISSN":["0011-5029"],"issn-type":[{"value":"0011-5029","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologics for the primary care physician: Review and treatment of psoriasis","name":"articletitle","label":"Article Title"},{"value":"Disease-a-Month","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.disamonth.2018.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}